Improving the Lives of Patients with Bipolar Disorder

Many factors, including something as simple as what we call psychotropic medications, can greatly impact outcomes in bipolar disorder. This educational activity will cover some key factors, including the use of “antipsychotics” in treating bipolar spectrum disorders as well as the impact of alcohol use disorder on the diagnosis and treatment of patients with bipolar disorder.

All sessions will be held in Pacific Time (PT).

Saturday, March 16, 2024

7:00 am - 8:00 am

“Anti-mood-chotic-abilizers”: Utilization of “Antipsychotics” in the Treatment of Bipolar Disorder

Manpreet K. Singh, MD, MS

Existing psychotropic nomenclature (e.g., “atypical antipsychotics”) falls quite short of being accurate or useful. Here, Dr. Manpreet Singh will take a deep dive into the issues with current nomenclature -including the impact on clinician behavior, patient outcomes, and stigma. The evolving proposals for revising psychotropic nomenclature to reflect pharmacology and mechanism will be investigated. Specifically, issues arising from the use of outdated “atypical antipsychotic” and “antidepressant” terminology will be explored as well as the evidence base, approvals, and indications of various psychotropic medication classes in the treatment of bipolar spectrum disorders.

After taking part in this educational activity, attendees will become a part of the nomenclature solution by ceasing use of antiquated terms and adopting updated, neuroscience-centered psychotropic nomenclature.

8:00 am - 9:00 am

Industry Session: Clinical Perspectives on a Treatment Option for Bipolar Depression (Bipolar I and II)

Henry A. Nasrallah, MD

Bipolar depression can be debilitating to patients, and difficulties in appropriate diagnosis and comorbidities can add to the challenge. This presentation will explore these challenges, as well as a treatment option approved for BOTH bipolar I and bipolar II depression in adults.

Sponsored by Intra-Cellular Therapies, Inc.

9:00 am – 9:05 am


9:05 am – 9:35 am

Poster Session: Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia: Pooled Results from the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials

Gerard Zitnik, PhD

Sponsored by Karuna Therapeutics, Inc.

9:35 am - 10:35 am

My Cup Runneth Over: Substance Use Disorders as a Complicating Factor in the Diagnosis and Treatment of Bipolar Disorder

Joseph F. Goldberg, MD

The negative impact of alcohol use disorder (AUD) on outcomes and quality of life for patients with bipolar disorder (BP) cannot be underestimated. In this presentation given by Dr. Joseph Goldberg, the prevalence and consequences of AUD in BP will be explored as well as strategies for working with patients and the care team to improve the recognition and effective treatment of AUD in the context of BP.

10:35 am - 11:00 am

The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.

Program Faculty

Joseph F. Goldberg, MD

Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY

Dr. Joseph Goldberg is a psychiatrist with 25 years of experience in academic research studying the features and treatment of mood disorders, particularly bipolar disorder and other forms of depression. He has spent many years conducting studies of mood disorders at academic medical centers such as the Payne Whitney Clinic/Weill Medical College of New York Presbyterian Hospital, the Zucker Hillside Hospital-North Shore Long Island Jewish Health System, and the Mount Sinai School of Medicine. Presently he supervises and teaches psychopharmacology to medical students and residents at the Mount Sinai School of Medicine, and maintains a private practice in Norwalk, CT. His goal is to integrate knowledge from that research background by taking a scholarly approach to psychopharmacology and applying it in tailored fashion to the unique needs of an individual patient. 

Dr. Goldberg has published over 180 original research publications in major psychiatric journals as well as 3 books on topics related to mood disorders, focusing on the use of anticonvulsant mood stabilizers and atypical antipsychotics, safety risks with antidepressants in bipolar disorder, management of drug side effects, features related to rapid cycling bipolar disorder, suicide risk in bipolar disorder, cognitive dysfunction in bipolar disorder, pharmacogenetics in bipolar disorder, comorbid psychiatric disorders in bipolar disorder, and the long-term functional course and outcome of bipolar disorder and depression. He serves on the board of directors of the American Society for Clinical Psychopharmacology and has lectured nationally and internationally at major scientific meetings and conferences, such as the American Psychiatric Association, the Society of Biological Psychiatry, the American Society for Clinical Psychopharmacology, the American College of Neuropsychopharmacology, the European College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologicum, the International Society for Affective Disorders, and the International Society for Bipolar Disorders. 

read more +

Manpreet K. Singh, MD, MS

Professor, Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA

Manpreet K. Singh, MD, MS, is Professor of Psychiatry and Behavioral Sciences at the UC Davis School of Medicine.

Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.

Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

read more +